Understanding Mental Health Risks of Cannabis Use Disorder in Youth
Recent clinical evidence reveals cannabis use disorder mental health risks in young adults, including elevated psychosis, anxiety, and depression. This study underscores the importance of awareness and informed clinical decision-making. Understanding…
Cannabis Science Digest: 3 Perinatal, Sleep, and Metabolic Signals Worth Watching
This cannabis science digest highlights perinatal cannabis research recruitment alongside sleep and metabolic signals. The perinatal paper improves research infrastructure for studying cannabis use in pregnancy. The sleep and metabolic studies offer…
Key Psychosis-Spectrum Glutamate Imaging and Cannabis Signals
This June 2026 digest highlights the psychosis-spectrum glutamate imaging cannabis study alongside a CBD case report in traumatic brain injury and preclinical neuroprotection research. These findings emphasize careful interpretation of cannabis brain…
Medical Cannabis for Chronic Pain: Function, Life Enjoyment, and Pain Scores
A new Minnesota medical cannabis study highlights medical cannabis chronic pain function by showing improvements in life enjoyment and daily activity. Many chronic pain patients report better function alongside pain score changes. This observational data…
What 26 Studies and 3,598 Patients Reveal About Cannabis and PTSD
This medical cannabis PTSD scoping review examines 26 studies and 3,598 patients. The controlled-trial evidence did not support broad PTSD symptom benefit, with one narrow signal for nabilone and nightmares. The article explains what the review shows,…
Medical Study Reveals Why Older Adults Choose Cannabis Edibles
A recent medical study examined cannabis edible use among older adults, revealing therapeutic rather than recreational motivations. Older adults cannabis edibles consumption focuses on pain management and mental health symptom relief when traditional…
Cannabis Schedule III Rescheduling Impact on Medical Research and Patients
The potential rescheduling of cannabis from Schedule I to Schedule III represents a significant regulatory shift that could reduce research barriers and accelerate clinical investigation. Cannabis schedule III rescheduling would lower DEA registration…
FDA Grants Cannabis Extract VER-01 Breakthrough Therapy Status for Pain
The FDA has awarded Breakthrough Therapy Designation to VER-01, a pharmaceutical-grade cannabis extract for chronic low back pain. This marks the first FDA breakthrough therapy cannabis designation for pain treatment, backed by Phase 3 trials showing…
Understanding Your Endocannabinoid System Through Scientific Research
Understanding the endocannabinoid system requires examining peer-reviewed scientific research rather than dismissing cannabis medicine entirely. Dr. Benjamin Caplan leads evidence-based cannabis care at CED Clinic, focusing on how endocannabinoid system…
Medical Cannabis Education Has Not Kept Pace With Clinical Reality
Medical cannabis provider knowledge may be far weaker than many clinicians believe. A survey of 879 U.S. healthcare professionals found large gaps between self-rated confidence and objective cannabis knowledge. The findings raise important questions…